bks cr narrow femoral nonporous - uncoated knee femur prosthesis
aa-med pty ltd -
bks uc tibial insert - prosthesis, knee, internal, insert component
aa-med pty ltd -
increlex
ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.
quinine bisulfate 300mg tablets
a a h pharmaceuticals ltd - quinine bisulfate - oral tablet - 300mg
quinine bisulfate 300mg tablets
sigma pharmaceuticals plc - quinine bisulfate - oral tablet - 300mg
quinine bisulfate 300mg tablets
almus pharmaceuticals ltd - quinine bisulfate - oral tablet - 300mg
quinine bisulfate 300mg tablets
de pharmaceuticals - quinine bisulfate - oral tablet - 300mg
quinine bisulfate 300mg tablets
viatris uk healthcare ltd - quinine bisulfate - oral tablet - 300mg
quinine bisulfate 300mg tablets
alliance healthcare (distribution) ltd - quinine bisulfate - oral tablet - 300mg
quinine bisulfate 300mg tablets
actavis uk ltd - quinine bisulfate - oral tablet - 300mg